Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' NowZacks Investment Research • 08/15/23
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial ResultsGlobeNewsWire • 08/03/23
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ETGlobeNewsWire • 06/21/23
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common StockGlobeNewsWire • 06/07/23
Vaxart Provides Business Update and Reports First Quarter 2023 Financial ResultsGlobeNewsWire • 05/04/23
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for NorovirusGlobeNewsWire • 03/17/23
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15GlobeNewsWire • 03/08/23
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29GlobeNewsWire • 11/22/22
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/08/22
VAXART, INC. (VXRT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 11/01/22
3 Supercharged Growth Stocks With 257% to 379% Upside, According to Wall StreetThe Motley Fool • 10/25/22
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8GlobeNewsWire • 10/20/22